Your browser doesn't support javascript.
loading
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa, Luciano J; Chhabra, Saurabh; Medvedova, Eva; Dholaria, Bhagirathbhai R; Schmidt, Timothy M; Godby, Kelly N; Silbermann, Rebecca; Dhakal, Binod; Bal, Susan; Giri, Smith; D'Souza, Anita; Hall, Aric C; Hardwick, Pamela; Omel, James; Cornell, Robert F; Hari, Parameswaran; Callander, Natalie S.
Afiliação
  • Costa LJ; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: ljcosta@uabmc.edu.
  • Chhabra S; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Medvedova E; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
  • Dholaria BR; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Schmidt TM; Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisc onsin, Madison, WI, USA.
  • Godby KN; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Silbermann R; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
  • Dhakal B; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Bal S; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Giri S; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • D'Souza A; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Hall AC; Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisc onsin, Madison, WI, USA.
  • Hardwick P; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Omel J; Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT), Omaha, NE, USA.
  • Cornell RF; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Hari P; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Callander NS; Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisc onsin, Madison, WI, USA.
Lancet Haematol ; 10(11): e890-e901, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37776872
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Ano de publicação: 2023 Tipo de documento: Article